Fate Therapeutics (FATE) Income from Continuing Operations (2012 - 2026)
Fate Therapeutics (FATE) reported Income from Continuing Operations of 31133000.0 for Q1 2026, up 17.95% on a YoY basis from 26395051.99 in Q1 2025, and up 4.21% quarter-over-quarter from 32501000.0 in Q4 2025.
Fate Therapeutics (FATE) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Fate Therapeutics has reported Income from Continuing Operations for 15 years, with the latest figure at 31133000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 17.95% year-over-year to 31133000.0; the trailing twelve-month figure through Mar 2026 stood at 129841000.0 (up 29.44% YoY), and the FY2025 full-year result was 136652000.0, up 29.19% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 31133000.0, up from 32501000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 24898000.0 in Q1 2023, with the low at 84604000.0 in Q3 2022.
- Historically, Income from Continuing Operations has averaged 49214235.29 across 5 years, with a median of 46582000.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 66.38% — and 2024, when it slumped 88.44%.
- Fate Therapeutics' Income from Continuing Operations stood at 61539000.0 in 2022, then gained by 29.05% to 43661000.0 in 2023, then tumbled by 32.55% to 57874000.0 in 2024, then jumped by 43.84% to 32501000.0 in 2025, then climbed by 4.21% to 31133000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 31133000.0 (Q1 2026), 32501000.0 (Q4 2025), and 32160000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - | -31.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.13 Mn |
| Dec 31, 2025 | -32.50 Mn |
| Sep 30, 2025 | -32.16 Mn |
| Jun 30, 2025 | -34.05 Mn |
| Mar 31, 2025 | -37.94 Mn |
| Dec 31, 2024 | -57.87 Mn |
| Sep 30, 2024 | -47.94 Mn |
| Jun 30, 2024 | -40.26 Mn |
| Mar 31, 2024 | -46.92 Mn |
| Dec 31, 2023 | -43.66 Mn |
| Sep 30, 2023 | -46.58 Mn |
| Jun 30, 2023 | -58.18 Mn |
| Mar 31, 2023 | -24.90 Mn |
| Dec 31, 2022 | -61.54 Mn |
| Sep 30, 2022 | -84.60 Mn |
| Jun 30, 2022 | -82.35 Mn |
| Mar 31, 2022 | -74.05 Mn |
| Dec 31, 2021 | -69.09 Mn |
| Sep 30, 2021 | -54.33 Mn |
| Jun 30, 2021 | -46.43 Mn |